CN102228441B - 一种右旋布洛芬缓释微丸及其制备方法 - Google Patents
一种右旋布洛芬缓释微丸及其制备方法 Download PDFInfo
- Publication number
- CN102228441B CN102228441B CN 201110171406 CN201110171406A CN102228441B CN 102228441 B CN102228441 B CN 102228441B CN 201110171406 CN201110171406 CN 201110171406 CN 201110171406 A CN201110171406 A CN 201110171406A CN 102228441 B CN102228441 B CN 102228441B
- Authority
- CN
- China
- Prior art keywords
- ibuprofen
- preparation
- pulvis talci
- micropill
- celphere
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- HEFNNWSXXWATRW-JTQLQIEISA-N dexibuprofen Chemical compound CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-JTQLQIEISA-N 0.000 title claims abstract description 60
- 238000002360 preparation method Methods 0.000 title claims abstract description 50
- 229960003428 dexibuprofen Drugs 0.000 title claims abstract description 32
- 238000013268 sustained release Methods 0.000 title claims abstract description 29
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 29
- 239000008188 pellet Substances 0.000 title claims abstract description 22
- 238000000576 coating method Methods 0.000 claims abstract description 51
- 239000011248 coating agent Substances 0.000 claims abstract description 49
- 239000003814 drug Substances 0.000 claims abstract description 39
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims abstract description 30
- 229940079593 drug Drugs 0.000 claims abstract description 22
- 239000011230 binding agent Substances 0.000 claims abstract description 14
- 239000000463 material Substances 0.000 claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000012530 fluid Substances 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 12
- 235000010603 pastilles Nutrition 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 7
- 239000006187 pill Substances 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 229920003139 Eudragit® L 100 Polymers 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 229960003943 hypromellose Drugs 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 claims description 2
- 239000011162 core material Substances 0.000 claims description 2
- 239000007888 film coating Substances 0.000 claims description 2
- 238000009501 film coating Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 description 33
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 31
- 229960001680 ibuprofen Drugs 0.000 description 30
- 210000002381 plasma Anatomy 0.000 description 26
- 239000000523 sample Substances 0.000 description 23
- 239000000243 solution Substances 0.000 description 23
- 238000012360 testing method Methods 0.000 description 21
- 239000002775 capsule Substances 0.000 description 17
- 241000700159 Rattus Species 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 10
- 230000008569 process Effects 0.000 description 7
- 239000004925 Acrylic resin Substances 0.000 description 6
- 229920000178 Acrylic resin Polymers 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 238000012417 linear regression Methods 0.000 description 6
- 229960002390 flurbiprofen Drugs 0.000 description 5
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000013558 reference substance Substances 0.000 description 4
- 238000004062 sedimentation Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007896 modified release capsule Substances 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000013062 quality control Sample Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000031737 Tissue Adhesions Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010041277 Sodium retention Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- -1 hydroxypropyl Chemical group 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000003808 methanol extraction Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000003361 porogen Substances 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110171406 CN102228441B (zh) | 2011-06-23 | 2011-06-23 | 一种右旋布洛芬缓释微丸及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110171406 CN102228441B (zh) | 2011-06-23 | 2011-06-23 | 一种右旋布洛芬缓释微丸及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102228441A CN102228441A (zh) | 2011-11-02 |
CN102228441B true CN102228441B (zh) | 2013-01-30 |
Family
ID=44841075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110171406 Active CN102228441B (zh) | 2011-06-23 | 2011-06-23 | 一种右旋布洛芬缓释微丸及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102228441B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103156855A (zh) * | 2013-03-21 | 2013-06-19 | 青岛正大海尔制药有限公司 | 一种酚咖缓释胶囊及其制备方法 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102600108A (zh) * | 2012-01-17 | 2012-07-25 | 广州科的信医药技术有限公司 | 一种氟比洛芬缓释胶囊及其制备方法 |
CN102920664B (zh) * | 2012-11-27 | 2013-10-02 | 臧杰 | 一种长效口服胰岛素缓控释微球的制备方法 |
CN104257665A (zh) * | 2014-09-01 | 2015-01-07 | 南京正大天晴制药有限公司 | 度他雄胺的口服固体制剂及其制备方法 |
CN105935445B (zh) * | 2016-03-28 | 2019-02-01 | 赤峰赛林泰药业有限公司 | 含2-(-4-异丁基苯基)丙酸右旋物的药物组合物及其制备方法 |
CN111135146A (zh) * | 2018-11-05 | 2020-05-12 | 珠海润都制药股份有限公司 | 一种布洛芬缓释微丸及其制备方法 |
CN110327309B (zh) * | 2019-07-17 | 2023-02-10 | 珠海润都制药股份有限公司 | 一种不发生粘丸的布洛芬缓释小丸 |
CN110755396B (zh) * | 2019-12-06 | 2022-04-08 | 北京悦康科创医药科技股份有限公司 | 一种布洛芬缓释小丸及其制备方法 |
CN110859809A (zh) * | 2019-12-17 | 2020-03-06 | 卓和药业集团有限公司 | 一种药物组合物及制备方法 |
CN112891322A (zh) * | 2021-03-26 | 2021-06-04 | 海南慧谷药业有限公司 | 右旋布洛芬制剂及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100870396B1 (ko) * | 2006-12-07 | 2008-11-25 | 보령제약 주식회사 | 심혈관계 질환 치료용 경구투여제제 |
KR20090047310A (ko) * | 2007-11-07 | 2009-05-12 | 한미약품 주식회사 | 덱시부프로펜을 함유하는 다층정제 |
CN101467989A (zh) * | 2007-12-27 | 2009-07-01 | 北京德众万全医药科技有限公司 | 一种含有布洛芬的缓释微丸 |
CN101862297B (zh) * | 2009-04-14 | 2012-07-25 | 上海医药工业研究院 | 一种非水溶性药物的缓释微丸、其缓释口腔崩解片及其制备方法 |
-
2011
- 2011-06-23 CN CN 201110171406 patent/CN102228441B/zh active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103156855A (zh) * | 2013-03-21 | 2013-06-19 | 青岛正大海尔制药有限公司 | 一种酚咖缓释胶囊及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102228441A (zh) | 2011-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102228441B (zh) | 一种右旋布洛芬缓释微丸及其制备方法 | |
JP2560019B2 (ja) | 活性化合物の放出を制御する新規な製剤およびその製造法 | |
US20230240994A1 (en) | Medicament-containing hollow particle | |
CN106370757B (zh) | 枸橼酸托法替布片剂药物组合物及质控方法 | |
JPS611614A (ja) | 経口投与用の徐放性医薬組成物 | |
CN106389371A (zh) | 枸橼酸托法替布药物组合物 | |
HUE027664T2 (en) | Nalbuphine-based preparations and their use | |
CN103610650B (zh) | 一种单硝酸异山梨酯缓释微丸及其制剂、制备方法 | |
CN104739773A (zh) | 一种右旋布洛芬缓释微丸及其制备方法 | |
CN102114011B (zh) | 一种布洛芬缓释制剂及其制备方法 | |
CN103655480B (zh) | 一种美托洛尔的缓释药物及其制备方法 | |
CN101322695B (zh) | 双氯芬酸钾缓释胶囊及其生产工艺 | |
CN102961363A (zh) | 氯化钾缓释胶囊 | |
CN104758265B (zh) | 一种雷诺嗪缓释片药物组合物及其制备方法 | |
CN109833309A (zh) | 美金刚缓释微片胶囊及其制备方法 | |
CN104042591B (zh) | 一种由酮洛芬和奥美拉唑组成的复方制剂及其制备方法 | |
CN102058564B (zh) | 扎托布洛芬缓控释制剂及其制备方法 | |
CN113509447B (zh) | 一种具有ido抑制活性的缓释片及其制备方法和应用 | |
CN101856331B (zh) | 精氨酸右旋布洛芬颗粒及其制备方法 | |
Rahul et al. | A review on immediate release drug delivery systems | |
CN104922078B (zh) | 非诺贝特迟释微丸、制备方法及应用 | |
CN105250233B (zh) | 右旋布洛芬肠溶缓释片及其制备方法 | |
JP6211044B2 (ja) | 薬物含有中空粒子 | |
CN105769807B (zh) | 一种含有非诺贝酸胆碱的药物组合物 | |
JP5044572B2 (ja) | イミダゾリルアルキル−ピリジンの安定な投薬製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: HUBEI SHUBANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: HUBEI SIBAO PHARMACEUTICAL CO., LTD. Effective date: 20121205 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20121205 Address after: Jingzhou City, Hubei province Xiantao 433008 Silk Road No. 1 Applicant after: Hubei Wellness Pharma Co., Ltd. Address before: Jingzhou City, Hubei province Xiantao 433008 Silk Road No. 1 Applicant before: Hubei Sibao Pharmaceutical Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: GRANDPHARMA (CHINA) CO., LTD. Free format text: FORMER OWNER: HUBEI SHUBANG PHARMACEUTICAL CO., LTD. Effective date: 20130327 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 433008 JINGZHOU, HUBEI PROVINCE TO: 430035 WUHAN, HUBEI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130327 Address after: 430035 Hubei province in Qiaokou District of Wuhan city Gutian Road No. 5 Patentee after: Yuanda Pharmaceutical (China) Co., Ltd. Address before: Jingzhou City, Hubei province Xiantao 433008 Silk Road No. 1 Patentee before: Hubei Wellness Pharma Co., Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20191115 Address after: 433000 Hubei province Xiantao silk Po No. 1 Patentee after: Hubei Wellness Pharma Co., Ltd. Address before: 430035 Hubei province in Qiaokou District of Wuhan city Gutian Road No. 5 Patentee before: Yuanda Pharmaceutical (China) Co., Ltd. |
|
TR01 | Transfer of patent right |